Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients

Abstract

Our results suggest that genetic polymorphisms in methotrexate transporters affect the toxicity but not the response of MTX treatment. Further studies should be performed to have more conclusive results.

Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis

“…Five studies were excluded because they discussed other polymorphisms or were review articles. Thus, in total 9 studies consisting of 14 comparisons met our inclusion criteria ( [11,12,13,14,15,16,17,18,19], . Fig.…”

“…Several studies have examined the potential contribution of the ABCB1 C3435T polymorphism in RA [11,12,13,14,15,16,17,18,19]. However, it remains controversial whether the ABCB1 C3435T polymorphism may be a marker of efficacy and toxicity of DMARDs including MTX.…”

Methotrexate Pharmacokinetic Genetic Variants are Associated with Outcome in Rheumatoid Arthritis Patients

“…The rs1051266 (G80A) variant in SLC19A1/RFC1 gene has been extensively studied in RA patients. It has been associated with the response in two studies [42,43] and with toxicity in two other studies [37,44]. However, other studies analyzing this variant did not show any significant associations with outcome [19,30,34,36,39,40].…”

P-glycoprotein in autoimmune rheumatic diseases

“…Due to this inhibition of ATIC, AICAR accumulates within the cells and inhibits adenosine deaminase. Hence, adenosine, which has potent anti-inflammatory action, is released outside the cells [56].…”